Finanzas de ENvue Medical Inc (FEED)FEEDENvue Medical Inc

ENvue Medical, Inc. (FEED) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is NanoVibronix, accounting for 81.8% of total sales, equivalent to $534.00K. Another important revenue stream is ENvue. Understanding this composition is critical for investors evaluating how FEED navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, ENvue Medical, Inc. maintains a gross margin of -111.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2290.38%, while the net margin is -2049.79%. These profitability ratios, combined with a Return on Equity (ROE) of -138.10%, provide a clear picture of how effectively FEED converts its operational activities into shareholder value.

In the context of the broader market, FEED competes directly with industry leaders such as VTAK and XAIR. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, FEED's gross margin of -111.30% stands against VTAK's 9.62% and XAIR's 12.73%. Such benchmarking helps identify whether ENvue Medical, Inc. is trading at a premium or discount relative to its financial performance.

ENvue Medical has shown declining revenue with total revenue of $239,000 in Q2 2026 and a net income loss of $12,164,000 in the same quarter. The gross margin is negative, indicating the company is struggling to maintain profitability.